Program
Gemcitabine
Also written as “gemcitabine”, “gemcitabine hydrochloride” and “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”.
Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Biliary Tract Neoplasms, led by 30 companies.
Drug pageGemcitabine: every studyMany companies study it; this page follows only the 128 they lead. All 1,376 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 681 open or running | phase 3since Nov 6, 2000 | Nov 6, 2000 | May 2027phase 2 · NCT05999994 |
| Hoffmann-La Rocheits history only | 181 open or running | phase 4since Mar 19, 2008 | Apr 17, 2007 | Mar 22, 2027phase 1 · NCT06624085 |
| Pfizerits history only | 50 open or running | phase 3since Jan 21, 2000 | Jan 21, 2000 | none ahead |
| GlaxoSmithKlineits history only | 40 open or running | phase 2since May 23, 2003 | May 23, 2003 | none ahead |
| Amgenits history only | 30 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 1since Apr 9, 2002 | Apr 9, 2002 | none ahead |
| NovoCureits history only | 20 open or running | phase 2since Oct 23, 2013 | Oct 23, 2013 | none ahead |
| Pierre Fabreits history only | 20 open or running | phase 2since Apr 16, 2012 | Apr 16, 2012 | none ahead |
| Sarah Cannon Research Instituteits history only | 20 open or running | phase 2since Apr 4, 2008 | Apr 4, 2008 | none ahead |
| Theriva Biologics SLits history only | 20 open or running | phase 1since Jan 21, 2014 | Jan 21, 2014 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Mar 24, 2016 | Mar 24, 2016 | none ahead |
| BeBetter Medits history only | 10 open or running | phase 2since Nov 11, 2024 | Nov 11, 2024 | none ahead |
| Betta Pharmaceuticalsits history only | 10 open or running | phase 4since Jul 16, 2014 | Jul 16, 2014 | none ahead |
| Coherus Oncologyits history only | 11 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| EBG MedAustronits history only | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| Eisaiits history only | 10 open or running | phase 2since May 17, 2010 | May 17, 2010 | none ahead |
| Hope Cancer Instituteits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Jiangsu Healthy Life Innovation Medical Technologyits history only | 11 open or running | no phasesince Sep 20, 2024 | Sep 20, 2024 | none ahead |
| Meyer Pharmaceuticalsits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Novaceaits history only | 10 open or running | phase 2since Sep 26, 2007 | Sep 26, 2007 | none ahead |
| Otsukaits history only | 10 open or running | phase 3since Jun 2, 2000 | Jun 2, 2000 | none ahead |
| Pharmacosmosits history only | 10 open or running | phase 2since Nov 18, 2016 | Nov 18, 2016 | none ahead |
| Pharmatech Oncologyits history only | 10 open or running | phase 2since Dec 7, 2001 | Dec 7, 2001 | none ahead |
| Relmada Therapeuticsits history only | 11 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Nov 2027phase 2 · NCT06663137 |
| RenovoRxits history only | 10 open or running | phase 1since Sep 8, 2014 | Sep 8, 2014 | none ahead |
| Shanghai Miracogenits history only | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Jul 17, 2018 | Jul 17, 2018 | none ahead |
| Smartwise Sweden ABits history only | 11 open or running | phase 2since Apr 5, 2026 | Apr 5, 2026 | Dec 2027phase 2 · NCT07575191 |
| Swedish Orphan Biovitrumits history only | 10 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| SynerGene Therapeuticsits history only | 11 open or running | phase 2since Dec 18, 2014 | Dec 18, 2014 | Dec 2026phase 2 · NCT02340117 |
Also a collaborator on its studies: Ono Pharmaceutical, Baili-Bio (Chengdu) Pharmaceutical, AbbVie, Bristol-Myers Squibb, Criterium, AstraZeneca, PharmaBio Development, Johnson & Johnson, PPD DEVELOPMENT, LP, Merck, Sanofi and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jun 20, 2007.
- Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03337698 · 314 enrolled · United States, Australia, France and more
- Dec 22, 2017Phase 2 study in Uterine Cervical NeoplasmsHoffmann-La Roche · NCT03386721 · 256 enrolled · United States, Belgium, France and more
- Jul 17, 2018Sino Biopharmaceutical’s first study: phase 3 study in Nasopharyngeal CarcinomaNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03601975 · 336 enrolled · China
- Mar 8, 2019Phase 2 study in Carcinoma, Transitional CellHoffmann-La Roche · NCT03869190 · 272 enrolled · United States, France, Greece and more
- May 10, 2021EBG MedAustron’s first study: no phase study in Pancreatic NeoplasmsNew to EBG MedAustronEBG MedAustron · NCT04894643 · 10 planned · Austria
- Feb 22, 2023Shanghai Miracogen’s first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to Shanghai MiracogenShanghai Miracogen · NCT05754853 · 290 planned · China
- Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
- Feb 29, 2024Phase 2 study in Pancreatic NeoplasmsNovoCure · NCT06390059 · 84 enrolled · Czechia, Germany, Spain and more
- Jun 10, 2024Coherus Oncology’s first study: phase 4 study in Nasopharyngeal NeoplasmsNew to Coherus OncologyCoherus Oncology · NCT06457503 · 100 planned · United States, Canada
- Aug 8, 2024Relmada Therapeutics’ first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to Relmada TherapeuticsRelmada Therapeutics · NCT06663137 · 70 planned · Israel
- Sep 20, 2024Jiangsu Healthy Life Innovation Medical Technology’s first study: no phase study in Biliary Tract NeoplasmsNew to Jiangsu Healthy Life Innovation Medical TechnologyJiangsu Healthy Life Innovation Medical Technology · NCT06611345 · 60 planned · China
- Oct 1, 2024Phase 1 study in LymphomaHoffmann-La Roche · NCT06624085 · 50 enrolled · United States, Puerto Rico
- Nov 11, 2024BeBetter Med’s first study: phase 2 study in Advanced Triple-Negative Breast CancerNew to BeBetter MedBeBetter Med · NCT06685796 · 65 enrolled · China
- Apr 5, 2026Smartwise Sweden AB’s first study: phase 2 study in Pancreatic Cancer Non-resectableNew to Smartwise Sweden ABSmartwise Sweden AB · NCT07575191 · 9 planned · Sweden
Ahead
- Dec 2026Primary completion: phase 2 study in Pancreatic NeoplasmsSynerGene Therapeutics · NCT02340117
- Dec 31, 2026Primary completion: no phase study in Pancreatic NeoplasmsEBG MedAustron · NCT04894643
- Mar 22, 2027Primary completion: phase 1 study in LymphomaHoffmann-La Roche · NCT06624085
- May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
TargetBeta
“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Hydroxyurearule | Norgine | phase 4 | 15 |
Studies
The newest 60 of 128 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07575191Pancreatic Cancer Non-resectable · Sweden | 2 | Recruiting | Smartwise Sweden AB | Dec 2027 | 9 |
| NCT06685796Advanced Triple-Negative Breast Cancer · China | 2 | Completed | BeBetter Med | Apr 20, 2026 | 65 |
| NCT06624085Lymphoma · United States, Puerto Rico | 1 | Active, not recruiting | Hoffmann-La Roche | Mar 22, 2027 | 50 |
| NCT06611345Biliary Tract Neoplasms · China | – | Recruiting | Jiangsu Healthy Life Innovation Medical Technology | Oct 30, 2026 | 60 |
| NCT06663137Non-Muscle Invasive Bladder Neoplasms · Israel | 2 | Recruiting | Relmada Therapeutics | Nov 2027 | 70 |
| NCT06457503Nasopharyngeal Neoplasms · United States, Canada | 4 | Recruiting | Coherus Oncology | Dec 2027 | 100 |
| NCT06390059Pancreatic Neoplasms · Czechia, Germany, Spain and more | 2 | Completed | NovoCure | Nov 18, 2025 | 84 |
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | May 2027 | 105 |
| NCT05754853Advanced or Metastatic Urothelium Cancer · China | 3 | Recruiting | Shanghai Miracogen | Oct 2025 | 290 |
| NCT04894643Pancreatic Neoplasms · Austria | – | Recruiting | EBG MedAustron | Dec 31, 2026 | 10 |
| NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more | 2 | Terminated | Hoffmann-La Roche | Oct 8, 2025 | 272 |
| NCT03601975Nasopharyngeal Carcinoma · China | 3 | UNKNOWN | Sino Biopharmaceutical | Jul 30, 2020 | 336 |
| NCT03386721Uterine Cervical Neoplasms · United States, Belgium, France and more | 2 | Terminated | Hoffmann-La Roche | Dec 30, 2021 | 256 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more | 2 | Completed | Hoffmann-La Roche | Feb 27, 2025 | 341 |
| NCT02981342Pancreatic Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Apr 20, 2018 | 106 |
| NCT02978716Triple Negative Breast Neoplasms · United States, Belgium, Bulgaria and more | 2 | Terminated | Pharmacosmos | Jun 28, 2019 | 102 |
| NCT02941601Thoracic Neoplasms · United States, Belgium, Germany and more | 2 | Withdrawn | Eli Lilly | Dec 2017 | 0 |
| NCT03887130Breast Neoplasms | 2 | Completed | Pierre Fabre | Apr 18, 2013 | 152 |
| NCT02807636Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Aug 31, 2022 | 1,213 |
| NCT02797977Fanconi Anemia · Spain, United Kingdom | 2 | Completed | GlaxoSmithKline | Apr 8, 2020 | 153 |
| NCT02723331Pancreatic Neoplasms · United States | 2 | Completed | Academic Thoracic Oncology Medical Investigators Consortium | Dec 8, 2022 | 48 |
| NCT02565641Pancreatic Neoplasms · Korea, Republic of | 2 | Completed | Hoffmann-La Roche | Sep 2006 | 63 |
| NCT02340117Pancreatic Neoplasms · United States | 2 | Active, not recruiting | SynerGene Therapeutics | Dec 2026 | 28 |
| NCT02237157Pancreatic Neoplasms · United States | 1 | Completed | RenovoRx | Sep 2016 | 20 |
| NCT02194556Adenocarcinoma · China | 4 | UNKNOWN | Betta Pharmaceuticals | Jul 2017 | 100 |
| NCT02045602Neoplasms · Spain | 1 | Completed | Theriva Biologics SL | May 2019 | 42 |
| NCT02045589Neoplasms · Spain | 1 | Completed | Theriva Biologics SL | Oct 2016 | 8 |
| NCT02006667Urologic Neoplasms · Germany | 2 | Completed | Hoffmann-La Roche | Jan 2010 | 13 |
| NCT01971281Pancreatic Neoplasms · Spain, Switzerland | 2 | UNKNOWN | NovoCure | Dec 2017 | 40 |
| NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more | 3 | Completed | Hoffmann-La Roche | Jan 30, 2015 | 208 |
| NCT01606748Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Eli Lilly | Jun 2013 | 35 |
| NCT01599013Carcinoma, Transitional Cell · France | 2 | Completed | Pierre Fabre | Oct 2013 | 69 |
| NCT01564251Lymphoma · United States, France | 1 | Completed | Hoffmann-La Roche | Jan 11, 2018 | 104 |
| NCT01359696Solid Tumor · United States, France | 1 | Completed | Hoffmann-La Roche | May 29, 2014 | 40 |
| NCT01324258Pancreatic Neoplasms · Japan | 1 | Completed | GlaxoSmithKline | Jul 8, 2013 | 19 |
| NCT01201265Breast Neoplasms · India | 2 | Completed | Hoffmann-La Roche | Apr 2015 | 40 |
| NCT01185847Non-Squamous Non-Small Cell Lung Cancer · Belgium, France, Germany and more | 2 | Completed | Hoffmann-La Roche | Sep 2012 | 90 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Jan 2014 | 280 |
| NCT01126749Urinary Bladder Neoplasms · United States, Germany, Netherlands and more | 2 | Terminated | Eisai | May 8, 2015 | 92 |
| NCT01077713Non-Squamous Non-Small Cell Lung Cancer · Italy | 2 | Completed | Hoffmann-La Roche | Jul 2014 | 86 |
| NCT01010945Adenocarcinoma · United States | 1 | Completed | Astellas Pharma | Jan 25, 2012 | 19 |
| NCT00846027Breast Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Dec 2011 | 90 |
| NCT00821327Urothelial Cancer · United States | 2 | Completed | Sarah Cannon Research Institute | Aug 2012 | 36 |
| NCT00701558Non-small Cell Lung Cancer Metastatic · Romania | 2 | Completed | Hoffmann-La Roche | Oct 2010 | 20 |
| NCT00678977Carcinoma, Non-Small-Cell Lung · Germany, United Kingdom | 1 | Completed | GlaxoSmithKline | Mar 30, 2010 | 22 |
| NCT00656084Recurrence | 2 | Completed | Sarah Cannon Research Institute | Jan 2007 | 16 |
| NCT00642733Pancreatic Neoplasms · Mexico | 4 | Terminated | Hoffmann-La Roche | Apr 2009 | 6 |
| NCT00623233Breast Neoplasms · United States | 2 | Completed | Eli Lilly | Jan 2011 | 52 |
| NCT00615446Neoplasms · United States | 1 | Completed | Pfizer | May 2009 | 44 |
| NCT00613730Pancreatic Neoplasms | 2 | Terminated | Amgen | Apr 2009 | 3 |
| NCT00536770Pancreatic Neoplasms · United States | 2 | Suspended | Novacea | 132 | |
| NCT00491127Lymphoma, Non-Hodgkin · Spain | 2 | Completed | Eli Lilly | 10 | |
| NCT00491114Urinary Bladder Neoplasms · Italy | 2 | Completed | Eli Lilly | 8 | |
| NCT00490880Urinary Bladder Neoplasms · Poland | 2 | Completed | Eli Lilly | 2 | |
| NCT00490711Carcinoma, Ovarian Epithelial · Slovakia | 2 | Completed | Eli Lilly | 7 | |
| NCT00490659Carcinoma, Non-Small-Cell Lung · Poland | 2 | Completed | Eli Lilly | 13 | |
| NCT00490399Biliary Tract Carcinoma · Korea, Republic of | 2 | Completed | Eli Lilly | 39 | |
| NCT00489996Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Eli Lilly | 100 | |
| NCT00489983Carcinoma, Non-Small-Cell Lung · Germany, Italy, United Kingdom | 2 | Completed | Eli Lilly | 91 |
How it is read
Names in the registry
- “Gemcitabine”, 113 entries
- “gemcitabine”, 52 entries
- “gemcitabine hydrochloride”, 17 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “EndoTAG-1 and Gemcitabine”, 3 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 53 studies
- Carcinoma, Non-Small-Cell Lung, 42 studies
- Breast Neoplasms, 24 studies
- Neoplasms, 10 studies
- Biliary Tract Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.